Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.

Taguchi H, Planque S, Nishiyama Y, Szabo P, Weksler ME, Friedland RP, Paul S.

Autoimmun Rev. 2008 May;7(5):391-7. doi: 10.1016/j.autrev.2008.03.004. Epub 2008 Apr 9. Review.

2.

Autoantibody-catalyzed hydrolysis of amyloid beta peptide.

Taguchi H, Planque S, Nishiyama Y, Symersky J, Boivin S, Szabo P, Friedland RP, Ramsland PA, Edmundson AB, Weksler ME, Paul S.

J Biol Chem. 2008 Feb 22;283(8):4714-22. Epub 2007 Dec 17.

3.

Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.

Paul S, Planque S, Nishiyama Y.

J Clin Immunol. 2010 May;30 Suppl 1:S43-9. doi: 10.1007/s10875-010-9414-5. Review.

4.

Beneficial catalytic immunity to abeta peptide.

Paul S, Planque S, Nishiyama Y.

Rejuvenation Res. 2010 Apr-Jun;13(2-3):179-87. doi: 10.1089/rej.2009.0958. Review.

5.

Specific amyloid β clearance by a catalytic antibody construct.

Planque SA, Nishiyama Y, Sonoda S, Lin Y, Taguchi H, Hara M, Kolodziej S, Mitsuda Y, Gonzalez V, Sait HB, Fukuchi K, Massey RJ, Friedland RP, O'Nuallain B, Sigurdsson EM, Paul S.

J Biol Chem. 2015 Apr 17;290(16):10229-41. doi: 10.1074/jbc.M115.641738. Epub 2015 Feb 27.

6.

Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.

Nitsch RM, Hock C.

Neurotherapeutics. 2008 Jul;5(3):415-20. doi: 10.1016/j.nurt.2008.05.013. Review.

7.

Modified immunotherapies against Alzheimer's disease: toward safer and effective amyloid clearance.

Wang YJ, Zhou HD, Zhou XF.

J Alzheimers Dis. 2010;21(4):1065-75. Review.

PMID:
21504118
8.

Immunotherapy for Alzheimer disease: the challenge of adverse effects.

Liu YH, Giunta B, Zhou HD, Tan J, Wang YJ.

Nat Rev Neurol. 2012 Aug;8(8):465-9. doi: 10.1038/nrneurol.2012.118. Epub 2012 Jul 3. Review.

PMID:
22751529
9.

[Development of antibodies for immunotherapy of Alzheimer's disease].

Matsumoto SE, Jin H, Takeda K, Hasegawa Y, Motoi Y, Hattori N, Tabira T.

Rinsho Shinkeigaku. 2012;52(11):1168-70. Japanese.

PMID:
23196552
10.

Immunotherapy for Alzheimer's disease.

Steinitz M.

Immunotherapy. 2009 May;1(3):461-9. doi: 10.2217/imt.09.3.

PMID:
20635962
11.

Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.

Lemere CA.

Prog Brain Res. 2009;175:83-93. doi: 10.1016/S0079-6123(09)17506-4. Review.

12.

Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease.

Söllvander S, Ekholm-Pettersson F, Brundin RM, Westman G, Kilander L, Paulie S, Lannfelt L, Sehlin D.

J Alzheimers Dis. 2015;48(1):63-72. doi: 10.3233/JAD-150236.

13.

Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

Deane R, Bell RD, Sagare A, Zlokovic BV.

CNS Neurol Disord Drug Targets. 2009 Mar;8(1):16-30. Review.

14.

Value in development of a TAPIR-like mouse monoclonal antibody to Abeta.

Sambamurti K, Pappolla MA, Jagannatha Rao KS.

J Alzheimers Dis. 2008 Jun;14(2):175-7. No abstract available.

15.

Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A.

Immunotherapy. 2012 Feb;4(2):213-38. doi: 10.2217/imt.11.170. Review.

PMID:
22339463
16.

Immunotherapy for Alzheimer's disease.

Wang W, Fan L, Xu D, Wen Z, Yu R, Ma Q.

Acta Biochim Biophys Sin (Shanghai). 2012 Oct;44(10):807-14. Epub 2012 Aug 16. Review.

PMID:
22899646
17.

Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies.

Hallé M, Tribout-Jover P, Lanteigne AM, Boulais J, St-Jean JR, Jodoin R, Girouard MP, Constantin F, Migneault A, Renaud F, Didierlaurent AM, Mallett CP, Burkhart D, Pilorget A, Palmantier R, Larocque D.

J Immunol Methods. 2015 Sep;424:64-79. doi: 10.1016/j.jim.2015.05.002. Epub 2015 May 19.

18.

Naturally occurring autoantibodies against β-Amyloid.

Bach JP, Dodel R.

Adv Exp Med Biol. 2012;750:91-9. doi: 10.1007/978-1-4614-3461-0_7. Review.

PMID:
22903668
19.

Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease.

Fukuchi K, Tahara K, Kim HD, Maxwell JA, Lewis TL, Accavitti-Loper MA, Kim H, Ponnazhagan S, Lalonde R.

Neurobiol Dis. 2006 Sep;23(3):502-11.

20.

Comparison of ELISA measurements of anti-Aβ concentrations and percentages of specific binding to Aβ between unfractionated intravenous immunoglobulin products and their purified anti-Aβ antibodies.

Klaver AC, Coffey MP, Smith LM, Loeffler DA.

Immunol Lett. 2013 Jul-Aug;154(1-2):7-11. doi: 10.1016/j.imlet.2013.07.008. Epub 2013 Aug 6.

PMID:
23928186

Supplemental Content

Support Center